Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLO3: Olaparib vs Chemotherapy in Relapsed Ovarian Cancer
NCT02282020Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of olaparib in ovarian cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Objective Response Rate. Started Feb 2015; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02282020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02282020.